Kezar Life Sciences, Inc. · NASDAQ:KZR
Kezar Life Sciences — Technical Presentation (November 2025)
14 slides from Kezar Life Sciences's technical presentation, Nov 10, 2025
Slide 1: Zetomipzomib Demonstrates Steroid Sparing Biochemical Remission in Autoimmune Hepatitis
Zetomipzomib, a First-in-Class Selective Immunoproteasome Inhibitor, Demonstrates Steroid Sparing Biochemical Remission in Patients with Relapsed or Insufficiently Responding Autoimmune Hepatitis in a Randomized, Double-blind, Placebo-controlled, Phase 2a Study Craig Lammert, MD Associate Professor
Slide 2: Disclosures
Disclosures • Consultant and Investigator for Kezar Life Sciences • Consultant Amgen, Eli Lilly, RegCell, Mirum • Executive Director, Autoimmune Hepatitis Association Slides are the property of the author and AALSD. Permission is required from both AASLD and the author for reuse. 2
Slide 3: Zetomipzomib Has Potential to Modulate Multiple Immune Pathways Underlying Autoimmune Hepatitis
Zetomipzomib Has Potential to Modulate Multiple Immune Pathways Underlying Autoimmune Hepatitis Cellular Dysfunction Observed Zetomipzomib Targets Multiple in AIH Immune Effector Cells Involved in Autoimmunity Zetomipzomib Significant Unmet Needs in AIH Treg Treg • Long-term corticosteroids and immu
Slide 4: Treatment Goals Are Focused on Biochemical Normalization and Low Daily Steroid Dose
Treatment Goals Are Focused on Biochemical Normalization and Low Daily Steroid Dose AASLD1 EASL2 Biochemical Remission ALT, AST, & IgG normalization by ALT, AST, & IgG normalization by Criteria 6 months 6 months Steroid Prednisone 20-40 mg/d with 0.5-1 mg/kg/d prednis(ol)one with Dose taper to ≤5-10
Slide 5: PORTOLA: Evaluate the Safety and Efficacy of Zetomipzomib in Relapsed or Insufficiently Responding AIH
PORTOLA: Evaluate the Safety and Efficacy of Zetomipzomib in Relapsed or Insufficiently Responding AIH Double-Blind Treatment (24 Weeks) Optional Open-Label Extension (up to 24 Weeks) Adult Randomization Zetomipzomib 60 mg SC QW + Prednisone 20-40 mg/day patients with 2:1 active AIH 1st dose 30 mg Z
Slide 6: PORTOLA: Demographics and Baseline Characteristics
PORTOLA: Demographics and Baseline Characteristics ITT Population (N=24) Placebo Zetomipzomib Total Placebo Zetomipzomib Total N=8 N=16 N=24 N=8 N=16 N=24 Age, median (min, max), Antibodies 54.0 (26, 72) 59.0 (25, 75) 57.5 (25, 75) years ANA positive, n (%) 6 (75.0) 14 (87.5) 20 (83.3) Female, n (%)
Slide 7: PORTOLA: Demographics and Baseline Characteristics – Cont'd
PORTOLA: Demographics and Baseline Characteristics – Cont’d ITT Population (N=24) Placebo* Zetomipzomib Total N=8 N=16 N=24 Concomitant medications at baseline* Prednisone (or equivalent)* n (%) 7 (87.5) 16 (100) 23 (95.8) Prednisone (or equivalent)†, dose in mg/day, median (min, max) 20 (20, 20) 20
Slide 8: Zetomipzomib Treatment Induces Steroid-Free Biochemical Remissions
Zetomipzomib Treatment Induces Steroid-Free Biochemical Remissions Prespecified Subset Analysis (N=21) AASLD and EASL Guidelines Zeto achieves lower steroid doses in relapsed/refractory AIH patients Target Treatment Goals All Complete Responses (CR) CR with Median Corticosteroid Dose Over Time Stero
Slide 9: Histologic Improvement and Remission Are Observed with Zetomipzomib at W24
Histologic Improvement and Remission Are Observed with Zetomipzomib at W24 Prespecified Subset Analysis (N=21) Histologic Remission Histologic Improvement (mHAI <4) (≥2 points in mHAI) 25 50 Proportion of Patients (%) Proportion of Patients (%) 21% 43% 20 3/14 3/14 40 6/14 15 14% 14% 29% 29% 30 1/7
Slide 10: PORTOLA Patient Journey
PORTOLA Patient Journey 67 y/o white male, AIH since 2021 (2.8 years), ANA+, normal IgG and receiving MMF 1.5 g/day + Prednisone 20 mg at Baseline PORTOLA Results • Steroid free CR Ineligible for OLE (Partial Hold) and flared by Week 28 • Histologic Remission • Liver Stiffness (Elastography): 25%
Slide 11: Zetomipzomib Treatment Demonstrates Alterations in Biomarker Activity Correlating With Biochemical Responses
Zetomipzomib Treatment Demonstrates Alterations in Biomarker Activity Correlating With Clinically Relevant Biochemical Responses in AIH • Decreased B cell populations and increased CD56bright NK cell populations are detected • Elevated Tregs and reduced neutrophil-related proteins are observed in CR
Slide 12: Favorable Safety and Tolerability Profile with Zetomipzomib Treatment
Favorable Safety and Tolerability Profile with Zetomipzomib Treatment Safety Population (DBTP N=23; OLE N=14) Double-blind Treatment Period (DBTP) Open-label Extension (OLE) Adverse Events Placebo Zetomipzomib DBTP Placebo DBTP Zetomipzomib N=7 N=16 N=5 N=9 n (%) n (%) n (%) n (%) Participants with
Slide 13: PORTOLA Marks First Successful Randomized Phase 2 Trial in Relapsed/Refractory AIH
PORTOLA Marks First Successful Randomized Phase 2 Trial in Relapsed/Refractory AIH • Zetomipzomib demonstrates rapid, durable, and steroid-sparing disease modifying activity in a difficult-to-treat population of patients with AIH • Favorable safety and tolerability profile observed with zetomipzomib
Slide 14: With deep appreciation to the patients, caregivers, investigators, and study site personnel
With deep appreciation to the patients, caregivers, investigators, and study site personnel whose commitment made this study possible.
Kezar Life Sciences — Technical Presentation (November 2025) on 6ix